Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Calaspargase PegolProcedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Dexrazoxane HydrochlorideDrug: DoxorubicinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideDrug: Imatinib MesylateDrug: MethotrexateOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: PegaspargaseDrug: PrednisoloneDrug: MercaptopurineDrug: MethylprednisoloneOther: Questionnaire AdministrationDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 475
- Registration Number
- NCT03007147
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- AC Camargo Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT02812654
- Locations
- 🇧🇷
A.C.Camargo Cancer Center, São Paulo, Sao Paulo, Brazil
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2021-09-20
- Target Recruit Count
- 80
- Registration Number
- NCT02808247
- Locations
- 🇧🇪
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium
🇫🇷Institut Bergonie, Bordeaux, France
🇧🇪Cliniques Universitaires Saint-Luc (121), Brussels, Belgium
Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT02784015
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Response-based Treatment of High-risk Neuroblastoma
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT02771743
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02732015
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Trial for the Treatment of Relapsed Osteosarcoma
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 7
- Registration Number
- NCT02718482
- Locations
- 🇮🇹
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
🇮🇹Istituto Giannina Gaslini, Genova, Italy
🇮🇹Università seconda di Napoli, Napoli, Italy
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT02703272
Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 53
- Registration Number
- NCT02686346
- Locations
- 🇧🇪
Clinique Universitaire Saint-Luc, Bruxelles, Belgium
🇧🇪CHU Dinant Godinne, Yvoir, Belgium
🇫🇷Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre, Caen, France
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT02677116
- Locations
- 🇺🇸
St Jude Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Childrens Hospital of Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.